1. High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline
- Author
-
Robert D. Valley, Yasheng Chen, James F. Howard, Hongyu An, Keith C. Kocis, Weili Lin, Zheng Fan, Manisha Chopra, William J. Powers, and Joseph Muenzer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Duchenne muscular dystrophy ,medicine.medical_treatment ,Sodium Chloride ,Young Adult ,Pressure ,Genetics ,Limb perfusion ,medicine ,Humans ,Muscular dystrophy ,Molecular Biology ,Saline ,Research Articles ,business.industry ,Gene Transfer Techniques ,Genetic Therapy ,Middle Aged ,medicine.disease ,Surgery ,Peripheral ,Muscular Dystrophy, Duchenne ,Perfusion ,Clinical trial ,Treatment Outcome ,Molecular Medicine ,Female ,business ,Limb-girdle muscular dystrophy - Abstract
We evaluated safety and feasibility of high-pressure transvenous limb perfusion in an upper extremity of adult patients with muscular dystrophy, after completing a similar study in a lower extremity. A dose escalation study of single-limb perfusion with 0.9% saline was carried out in nine adults with muscular dystrophies under intravenous analgesia. Our study demonstrates that it is feasible and definitely safe to perform high-pressure transvenous perfusion with 0.9% saline up to 35% of limb volume in the upper extremities of young adults with muscular dystrophy. Perfusion at 40% limb volume is associated with short-lived physiological changes in peripheral nerves without clinical correlates in one subject. This study provides the basis for a phase 1/2 clinical trial using pressurized transvenous delivery into upper limbs of nonambulatory patients with Duchenne muscular dystrophy. Furthermore, our results are applicable to other conditions such as limb girdle muscular dystrophy as a method for delivering regional macromolecular therapeutics in high dose to skeletal muscles of the upper extremity.
- Published
- 2015